<DOC>
	<DOCNO>NCT02822937</DOCNO>
	<brief_summary>This study adults assess sensitivity Project : EVO Monitor cognitive measurement two short-acting cognitively active pharmacological agent . The participant receive placebo , two pharmacological agent randomize order three in-clinic study day . During study day clinic , participant use Project : EVO Monitor another cognitive task day .</brief_summary>
	<brief_title>Sensitivity Project : EVO Monitor Cognitive Measurements Pharmacological Agents</brief_title>
	<detailed_description>This study adults age 40 55 assess sensitivity Project : EVO Monitor cognitive measurement two short-acting cognitively active pharmacological agent , methylphenidate ( MPH ) triazolam ( TRZ ) . The participant receive placebo , MPH , TRZ randomize order three in-clinic study day . All drug administration cognitive test take place clinic medical staff supervision . During study day clinic , participant use Project : EVO Monitor short digit symbol substitution task ( DSST ) 8 time day . A minimum 48 hour need study day . The investigator plan evaluate 18 participant study .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Triazolam</mesh_term>
	<criteria>1 . Age 4055 time inform consent 2 . Ability follow write verbal instruction ( English ) . 3 . Weight 140 lbs 240 lb . 4 . Male female ( Gendermatched ) . 5 . Ability comply test requirement . 1 . Known adverse reaction study medication . 2 . Known nonresponse paradoxical response study medication . 3 . Current , control ( require restrict medication ) uncontrolled , selfreported psychiatric diagnosis significant symptom posttraumatic stress disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive anxiety disorder , conduct disorder , attention deficit disorder , autism spectrum disorder , symptomatic manifestation opinion Investigator may confound study data/assessments . 4 . Current selfreported community diagnosis cognitive ailment dementia , Alzheimer 's disease , stroke , traumatic brain injury , diseases opinion Investigator may confound study data/assessments . 5 . Current diagnosis severe learn disorder , dyslexia , dyscalculia . 6 . Current subjective complaint inattention memory loss . 7 . Currently undergo psychotherapy , behavioral therapy , occupational therapy . 8 . Current use psychotropic medication , prescription otherwise . 9 . Motor condition prevents game playing , report parent observe investigator . 10 . Impaired visual acuity , define difficulty reading inform consent even corrective lens . 11 . Lifetime history suspect substance abuse dependence . 12 . Current use ( define within last 30 day ) product nicotine , e.g . cigarette , chew tobacco , ecigarettes , nicotine patch , nicotine gum . 13 . History seizure ( exclusive febrile seizure ) , tic disorder , significant tic , current diagnosis Tourette 's Disorder . 14 . Taken part clinical trial within 30 day prior screen . 15 . Diagnosis patientreported color blindness . 16 . Regular use psychoactive drug opinion Investigator may confound study data/assessments . 17 . Pregnancy . 18 . Currently nurse breastfeed . 19 . Resting heart rate &gt; 100 beats/min . 20 . Systolic blood pressure &gt; 150 mm/Hg . 21 . History cardiac abnormality . 22 . History glaucoma . 23 . Current use monoamine oxidase inhibitor , HIV protease inhibitor , ranitidine , isoniazid , ketoconazole , itraconazole , nefazodone azoletype antifungal agent drug contraindicate use study medication . 24 . Any medical condition opinion investigator may confound study data/assessments . 25 . Any medical condition opinion investigator prohibit administration study medication .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>